EL7.AI
Strategy BuilderCOT DataAdvanced NewsResearchNewEarnings CalendarEconomic Calendar
We use cookiesPrivacy Policy
EL7.AIEL7.AI

AI Financial Intelligence
Professional analysis of central bank decisions

© 2026 EL7.AI. All rights reserved.

Markets

  • News
  • Forex
  • Stocks
  • Crypto
  • Gold
  • Commodities
  • Indices
  • ETFs

Analysis

  • Fed
  • ECB
  • BLS
  • COT
  • Economic Calendar

Learn

  • Service Guide
  • Oil

Company

  • About
  • Contact
  • Data Methodology
  • AI Disclosure
  • Pricing
  • Enterprise
  • Terms
  • Privacy
  • Security
  • WhatsApp
Status data is currently unavailable

The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

ResolvedStocks

Pacira Sells iovera to Zimmer Biomet in Up to $140M Deal to Focus on Drug Growth

First Detected: Jul 1, 2026, 2:47 PM
Last Update: 2 months ago
4 articles·3 stories

Event Summary

On July 1, Pacira (PCRX) sold its iovera franchise to Zimmer Biomet (ZBH) in a deal worth up to $140M to sharpen its focus on biopharmaceutical growth. On July 2, U.S. Physical Therapy purchased a majority stake in a physical therapy practice. Additionally, Orthofix Medical shares rose following a decision by the Centers for Medicare & Medicaid Services (CMS) to reverse its stance on non-invasive bone growth stimulators.

Timeline

Orthofix Stock Rallies as CMS Reverses Stance on Bone Growth Stimulators
Jul 2, 2026, 9:45 PMImpact: 6
U.S. Physical Therapy Acquires Majority Stake in Practice to Drive Growth
Jul 2, 2026, 3:16 PMImpact: 4
Pacira Sells iovera to Zimmer Biomet in Up to $140M Deal to Focus on Drug Growth
Jul 1, 2026, 2:47 PMImpact: 4

Price Impact

Since event start
PCRX+5.27%
ZBH+17.52%
USPH+10.28%
OFIX-0.64%